Discontinued Product

Salirasib (Cat. No. 4989) has been withdrawn from sale for commercial reasons.
Description: Ras inhibitor; also induces autophagy
Chemical Name: 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic acid
Purity: ≥98% (HPLC)
Citations (2)
Reviews (1)
Literature (4)
Pathways (1)

Biological Activity for Salirasib

Salirasib is an inhibitor of active Ras proteins. Displaces active Ras from the plasma membrane; impairs downstream signaling and inhibits proliferation of endometrial carcinoma cells. Also facilitates Ras degradation. Shown to induce autophagy in several human cancer cell lines.

Technical Data for Salirasib

M. Wt 358.54
Formula C22H30O2S
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 162520-00-5
PubChem ID 5469318
Smiles C\C(CC/C=C(C)/CC/C=C(C)/C)=C/CSC1=CC=CC=C1C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Salirasib

Certificate of Analysis / Product Datasheet
Select another batch:

References for Salirasib

References are publications that support the biological activity of the product.

Schmukler et al (2013) Ras inhibition enhances autophagy, which partially protects cells from death. Oncotarget 4 142 PMID: 23370967

Faigenbaum et al (2013) Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Oncotarget 4 316 PMID: 23530112

Haklai et al (1998) Dislodgement and accelerated degradation of Ras. Biochemistry 37 1306 PMID: 9477957

View Related Products by Product Action

View all Ras GTPase Inhibitors

Keywords: Salirasib, Salirasib supplier, Ras, inhibitors, inhibits, induces, autophagy, Autophagy, GTPases, 4989, Tocris Bioscience

2 Citations for Salirasib

Citations are publications that use Tocris products. Selected citations for Salirasib include:

Li et al (2018) Is Ras a potential target in treatment against cutaneous squamous cell carcinoma?. J Cancer 9 3373 PMID: 30271499

Lee et al (2015) A systems-biological study on the identification of safe and effective molecular targets for the reduction of ultraviolet B-induced skin pigmentation. J Virol 5 10305 PMID: 25980672

Reviews for Salirasib

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Salirasib?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Salirasib blocks LPA-mediated COX-2 expression.
By Anonymous on 12/13/2018
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: Osteosarcoma

Human osteosarcoma cells were incubated with 20 μM Salirasib for 30 min prior to treatment with 10 μM LPA to estimate COX-2 expression using Western blot analysis. Salirasib abolished LPA-induced COX-2 expression.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Cancer Metabolism Research Product Guide

Cancer Metabolism Research Product Guide

This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:

RAS Oncoproteins Scientific Review

RAS Oncoproteins Scientific Review

Written by Kirsten L. Bryant, Adrienne D. Cox and Channing J. Der, this review provides a comprehensive overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutic vulnerabilities are explored. This review also includes a detailed section on RAS drug discovery and targeting synthetic lethal interactors of mutant RAS. Compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Pathways for Salirasib

Akt Signaling Pathway

Akt Signaling Pathway

The Akt signaling pathway plays a key role in the mediation of protein synthesis, metabolism, proliferation and cell cycle progression. It may be referred to as a 'prosurvival' pathway.
MAPK Signaling Pathway

MAPK Signaling Pathway

The mitogen-activated protein kinase pathway evokes an intracellular signaling cascade in response to extracellular stimuli such as heat and stress. It can influence cell division, metabolism and survival.